INTERPACE BIOSCIENCES, INC. (IDXG) Free cash flow 2017–2025
INTERPACE BIOSCIENCES, INC. (IDXG) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$5.5MFY2025 · since FY2017: -$15.3M → $5.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $5.5M | +45.2% |
| FY2024 | $3.8M | +13.6% |
| FY2023 | $3.3M | +141.4% |
| FY2022 | -$8.0M | +11.7% |
| FY2021 | -$9.1M | +41.7% |
| FY2020 | -$15.6M | +18.5% |
| FY2019 | -$19.1M | -109.3% |
| FY2018 | -$9.1M | +40.3% |
| FY2017 | -$15.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IDXG financial trends
IDXG RevenueIDXG Net incomeIDXG Net marginIDXG Gross profitIDXG Gross marginIDXG Operating incomeIDXG Operating marginIDXG Operating cash flowIDXG Capital expendituresIDXG Return on equityIDXG Stock buybacksIDXG Dividends paidIDXG Total assetsIDXG Total liabilitiesIDXG Shareholders’ equityIDXG overview →